Cargando…
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
PURPOSE: The addition of trastuzumab to adjuvant chemotherapy has improved the outcome of human epidermal growth-factor receptor 2 (HER2)-positive breast cancer. Uncertainty remains about the optimal timing of trastuzumab treatment. Therefore, we compared long-term outcome after concurrent versus se...
Autores principales: | Dackus, Gwen M. H. E., Jóźwiak, Katarzyna, van der Wall, Elsken, van Diest, Paul J., Hauptmann, Michael, Siesling, Sabine, Sonke, Gabe S., Linn, Sabine C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921067/ https://www.ncbi.nlm.nih.gov/pubmed/33113088 http://dx.doi.org/10.1007/s10549-020-05978-8 |
Ejemplares similares
-
Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021) -
Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands
por: van Dooijeweert, Carmen, et al.
Publicado: (2019) -
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial
por: Schouten, Philip C., et al.
Publicado: (2016) -
Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients
por: Witteveen, Annemieke, et al.
Publicado: (2015) -
Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study
por: Dackus, Gwen MHE, et al.
Publicado: (2017)